Product news

Share this article:

Novo Nordisk discontinued its experimental AERx inhaler and took a charge of $260 million in 2007, saying the product offered little clinical benefit. “Pfizer's decision on Exubera prompted this,” Mads Krogsgaard Thomsen, Novo's chief scientific officer, in  said in a published report. “We have realized that the trend is for physicians to start treatment with something simple rather than a device that has to be loaded with insulin for each mealtime use.” A Novo spokeswoman said that a “significant number'” of 360 jobs at the company's Hayward, California site will be “affected.”

Three Rivers Pharmaceutical has finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International. Valeant is receiving $91 million from Three Rivers for the procurement.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.